IL98455A - Cancer-associated scm-recognition factor and its method of use - Google Patents

Cancer-associated scm-recognition factor and its method of use

Info

Publication number
IL98455A
IL98455A IL9845591A IL9845591A IL98455A IL 98455 A IL98455 A IL 98455A IL 9845591 A IL9845591 A IL 9845591A IL 9845591 A IL9845591 A IL 9845591A IL 98455 A IL98455 A IL 98455A
Authority
IL
Israel
Prior art keywords
factor
scm
cancer
useful
scm factor
Prior art date
Application number
IL9845591A
Other languages
English (en)
Other versions
IL98455A0 (en
Original Assignee
Cercek Lea
Cercek Boris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cercek Lea, Cercek Boris filed Critical Cercek Lea
Publication of IL98455A0 publication Critical patent/IL98455A0/xx
Publication of IL98455A publication Critical patent/IL98455A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4745—Cancer-associated SCM-recognition factor, CRISPP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IL9845591A 1990-06-18 1991-06-11 Cancer-associated scm-recognition factor and its method of use IL98455A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/539,686 US5270171A (en) 1987-03-06 1990-06-18 Cancer-associated SCM-recognition factor, preparation and method of use

Publications (2)

Publication Number Publication Date
IL98455A0 IL98455A0 (en) 1992-07-15
IL98455A true IL98455A (en) 1997-01-10

Family

ID=24152242

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9845591A IL98455A (en) 1990-06-18 1991-06-11 Cancer-associated scm-recognition factor and its method of use

Country Status (11)

Country Link
US (2) US5270171A (de)
EP (1) EP0537276B1 (de)
JP (1) JPH05509308A (de)
KR (1) KR930700536A (de)
AT (1) ATE177116T1 (de)
AU (1) AU665337B2 (de)
CA (1) CA2084767A1 (de)
DE (1) DE69130950D1 (de)
FI (1) FI925736A7 (de)
IL (1) IL98455A (de)
WO (1) WO1991019736A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580561A (en) * 1987-03-06 1996-12-03 Cercek; Boris Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
WO1994003806A1 (en) * 1992-08-10 1994-02-17 Boris Cercek Immunochemical assays for cancer-associated scm recognition factor
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1997018322A2 (de) 1995-11-16 1997-05-22 Dahm Michael W Verfahren zur quantifizierung von tumorzellen in einer körperflüssigkeit und dazu geeignete testkits
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
DE19804372A1 (de) 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
DE19904267A1 (de) 1999-02-03 2000-08-10 Michael W Dahm Verfahren zur Anreicherung von Tumorzellen aus einer Körperflüssigkeit und dazu geeigneter Kit
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6750037B2 (en) 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US20030105595A1 (en) * 2001-07-13 2003-06-05 Bader Joel S. Chi square tests for gene expression
DE60307545T2 (de) * 2002-06-21 2007-10-04 Adair, Edwin L., Castle Pines Village Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose
US7869033B2 (en) * 2003-12-24 2011-01-11 Vadivel Masilamani Cancer detection by optical analysis of body fluids
US8208142B2 (en) * 2003-12-24 2012-06-26 King Salid University Lung cancer detection by optical analysis of body fluids
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
US7264794B2 (en) * 2004-12-17 2007-09-04 The General Hospital Methods of in vivo cytometry
US7491502B2 (en) * 2004-12-17 2009-02-17 The General Hospital Corporation In vivo flow cytometry system and method
US7261724B2 (en) 2005-04-14 2007-08-28 Ethicon Endo-Surgery, Inc. Surgical clip advancement mechanism
US7740641B2 (en) 2005-04-14 2010-06-22 Ethicon Endo-Surgery, Inc. Clip applier with migrational resistance features
US7288098B2 (en) 2005-04-14 2007-10-30 Ethicon Endo-Surgery, Inc. Force limiting mechanism for medical instrument
US7686820B2 (en) 2005-04-14 2010-03-30 Ethicon Endo-Surgery, Inc. Surgical clip applier ratchet mechanism
US8523882B2 (en) 2005-04-14 2013-09-03 Ethicon Endo-Surgery, Inc. Clip advancer mechanism with alignment features
US7297149B2 (en) 2005-04-14 2007-11-20 Ethicon Endo-Surgery, Inc. Surgical clip applier methods
US8038686B2 (en) 2005-04-14 2011-10-18 Ethicon Endo-Surgery, Inc. Clip applier configured to prevent clip fallout
WO2008137693A2 (en) * 2007-05-04 2008-11-13 The General Hospital Corporation D/B/A Massachusetts General Hospital Retinal flow cytometry
US8574859B2 (en) * 2008-03-27 2013-11-05 The General Hospital Corporation In vivo flow cytometry based on cellular autofluorescence
US8262679B2 (en) 2009-10-09 2012-09-11 Ethicon Endo-Surgery, Inc. Clip advancer
US8267945B2 (en) 2009-10-09 2012-09-18 Ethicon Endo-Surgery, Inc. Clip advancer with lockout mechanism
BR112014009401B1 (pt) 2011-10-19 2021-02-17 Ethicon Endo-Surgery, Inc. instrumento de fixação cirúrgica
CA3077804C (en) * 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
ITRM20120028A1 (it) * 2012-01-25 2013-07-26 Natalia Malara Metodo per isolare cellule tumorali circolanti.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001080A (en) * 1972-10-20 1977-01-04 Piktor Limited Production of immunological materials
SU445690A1 (ru) * 1973-06-04 1974-10-05 Витебский государственный медицинский институт Способ определени сенсибилизации лейкоцитов
IL57135A (en) * 1979-04-25 1982-12-31 Abic Project Partnership Method for the determination of a factor or factors which enhances the cortisol metabolism in lymphocytes or leucocytes
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3333752A1 (de) * 1983-09-19 1985-04-11 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive peptide
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
WO1986003007A1 (en) * 1984-11-16 1986-05-22 Chou Iih Nan Assay for the detection of epigenetic toxic substances
CA1305024C (en) * 1986-05-27 1992-07-14 Boris Cercek Method for measuring polarized fluorescence emissions
CA1336404C (en) * 1987-03-06 1995-07-25 Boris Cercek General cancer-associated scm-recognition factor, preparation and method of use
JPH03503051A (ja) * 1988-03-02 1991-07-11 サーセク・ボリス 合成ｓｃｍ‐活性癌認識ペプチド
JPH03503763A (ja) * 1988-03-11 1991-08-22 サーセク・ボリス 一般的な癌‐関連ｓｃｍ‐認識因子、調製品及び使用方法
JPH04502205A (ja) * 1988-10-21 1992-04-16 サーセツク，ボリス 細胞質マトリックスの構造性（ｓｃｍ）テスト用の、特定密度の血液細胞の調製

Also Published As

Publication number Publication date
IL98455A0 (en) 1992-07-15
US5270171A (en) 1993-12-14
ATE177116T1 (de) 1999-03-15
FI925736A0 (fi) 1992-12-17
EP0537276A1 (de) 1993-04-21
AU8287791A (en) 1992-01-07
JPH05509308A (ja) 1993-12-22
US5443967A (en) 1995-08-22
WO1991019736A3 (en) 1992-02-20
WO1991019736A2 (en) 1991-12-26
CA2084767A1 (en) 1991-12-19
AU665337B2 (en) 1996-01-04
EP0537276B1 (de) 1999-03-03
KR930700536A (ko) 1993-03-15
FI925736A7 (fi) 1992-12-17
DE69130950D1 (de) 1999-04-08

Similar Documents

Publication Publication Date Title
IL98455A (en) Cancer-associated scm-recognition factor and its method of use
Boyer et al. Hemoglobin biosynthesis in murine virus-induced leukemic cells in vitro: structure and amounts of globin chains produced
Perlmann et al. In vitro studies of ulcerative colitis: II. Cytotoxic action of white blood cells from patients on human fetal colon cells
Doljanski et al. Cell surface shedding—the phenomenon and its possible significance
Hollinshead et al. Separation of skin reactive intestinal cancer antigen from the carcinoembryonic antigen of Gold
Kassenaar et al. The incorporation of glycine into globin and the synthesis of heme in vitro in duck erythrocytes
Burger et al. Human transfer factor: effects on lymphocyte transformation
EP0221748A2 (de) Verfahren zur Herstellung von menschlichen Antikörpern
Geller et al. Electrophoresis of saliva
Nathenson et al. Biochemical similarity of papain-solubilized H-2d alloantigens from tumor cells and from normal cells
Thomas et al. The separation of human B lymphocytes on a digestible immunoadsorbent column
Aarli Binding of γ-globulin fragments to muscle tissue
Cercek et al. Induction of PHA response in mouse bone marrow cells by thymic extracts as studied by changes in the structuredness of cytoplasmic matrix
NO924844L (no) Cancerassosiert scm-gjenkjennelsesfaktor, fremgangsmaate for dens fremstilling og anvendelse av faktoren
Embleton Significance of tumour associated antigens on human colonic carcinomata
Hernandez et al. Production and secretion of Leishmania braziliensis proteins
Vanhaelen et al. Increased sensitivity of lymphocytes from patients with Hodgkin's disease to concanavalin A-induced suppressor cells.
McCabe et al. Immunosuppression by human skin cancers
Sundqvist et al. Anchorage and lymphocyte function II. Contact with non-cellular surfaces, cell density and T-cell activation
Norberg et al. The reaction of cells with anti-actin sera in relation to the amount of cellular actin
AU624071B2 (en) General cancer-associated scm-recognition factor, preparation and method of use
Boto et al. Variation in the synthesis of membrane proteins of human T lymphocytes during mitogenic activation: recognition of a 70,000 dalton protein with anti-p23, 30 heteroantiserum and a novel 42,000 dalton protein with anti-p44, 12 heteroantiserum.
Reiss et al. Fixation of complement to fragments of antibody
Goeken et al. Immunosuppressive activity of isolated rat and human fetoproteins
Poros et al. Expression of Helix pomatia (HP) haemagglutinin receptors on cytolytic lymphocytes activated in mixed cultures

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees